Anxiety disorders

BehaVR Partners to Advance Virtual Reality for Social Anxiety Disorder

Retrieved on: 
Wednesday, August 5, 2020
Research, Mental health, Technology, Other Technology, Software, Hardware, General Health, Health, VoIP, Science, Psychiatry, Human behavior, Articles, Anxiety disorders, Abnormal psychology, Psychiatric diagnosis, Anxiety, Emotions, Virtual reality, Mental health, Social anxiety disorder, Mental disorder, BehaVR, Sumitomo Dainippon Pharma Co., Ltd., Sunovion Pharmaceuticals Inc.

BehaVR , a leading innovator of virtual reality digital wellness and digital therapeutics experiences, today announced that it has begun a new partnership aimed at leveraging virtual reality experiences to address critical unmet needs in social anxiety disorder (SAD), an underreported and undertreated mental health condition.

Key Points: 
  • BehaVR , a leading innovator of virtual reality digital wellness and digital therapeutics experiences, today announced that it has begun a new partnership aimed at leveraging virtual reality experiences to address critical unmet needs in social anxiety disorder (SAD), an underreported and undertreated mental health condition.
  • to create a general wellness product that uses virtual reality (VR) to assist in the management of SAD.
  • According to the Social Anxiety Association , social anxiety disorder is the third largest mental health condition in the world today, estimated to affect as much as 7 percent of the population more than 17 million people in the U.S. alone.
  • Virtual reality has the potential to make good care and management for social anxiety disorder more accessible to people around the world, said Aaron Gani , founder and CEO of BehaVR.

COVID-19 Impacts: Post-Traumatic Stress Disorder (PTSD) Therapeutics Market will Accelerate at a CAGR of Over 9% through 2020-2024 | Rising Prevalence of PTSD to Boost Growth | Technavio

Retrieved on: 
Monday, August 3, 2020
General Health, Pharmaceutical, Health, Mental health, Articles, Psychiatry, Human behavior, Adverse childhood experiences, Anxiety disorders, Stress, Aftermath of war, Posttraumatic stress disorder, Psychological trauma, Post-traumatic

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • Growing at a CAGR of over 9%, the market growth will accelerate during the forecast period of 2020-2024.
  • Rising prevalence of PTSD is one of the key factors driving market growth.
  • Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024: Segmentation
    Post-Traumatic Stress Disorder (PTSD) Therapeutics Market is segmented as below:

2020 Generalized Anxiety Disorder (GAD) - Market Insights, Epidemiology & Market Forecast - ResearchAndMarkets.com

Retrieved on: 
Monday, July 27, 2020
Pharmaceutical, Health, Mental health, Psychiatry, Psychology, Psychiatric diagnosis, Human behavior, Emotions, Anxiety disorders, RTT, Generalized anxiety disorder, Anxiety, Gad, Worry

The "Generalized Anxiety Disorder (GAD) - Market Insights, Epidemiology, and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Generalized Anxiety Disorder (GAD) - Market Insights, Epidemiology, and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Generalized Anxiety Disorder (GAD)- Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Generalized Anxiety Disorder in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Generalized Anxiety Disorder Generalized anxiety disorder (GAD) is characterized by persistent, excessive, and unrealistic worry about everyday things.
  • The Generalized Anxiety Disorder epidemiology division provides insights about historical and current patient pool and forecasted trends for every 7 major countries.

VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder

Retrieved on: 
Thursday, July 23, 2020
Psychiatry, Anxiety disorders, Psychiatric diagnosis, Psychology, RTT, Anxiolytics, Abnormal psychology, 4-Androstadienol, Social anxiety disorder, Anxiety, Social anxiety, Generalized anxiety disorder

Food and Drug Administration(FDA) regarding Phase 3 development of PH94B for the acute treatment of anxiety in adult patients with social anxiety disorder (SAD).

Key Points: 
  • Food and Drug Administration(FDA) regarding Phase 3 development of PH94B for the acute treatment of anxiety in adult patients with social anxiety disorder (SAD).
  • PH94B is an investigational rapid-onset neurosteroid nasal spray that is fundamentally differentiated from all FDA-approved treatments for anxiety disorders.
  • As in the successful Phase 2 study of PH94B in SAD, the study will involve a single laboratory-simulated anxiety-provoking public speaking challenge.
  • VistaGen is preparing for Phase 3 clinical development of PH94B as a potentialnew generation fast-acting, non-sedating, non-addictive acute treatment of anxiety in adults with social anxiety disorder (SAD).

Veterinarians Fear Dogs will Experience Sudden Spike in Separation Anxiety As Pet Owners Return to Work

Retrieved on: 
Wednesday, July 22, 2020
Organisms, Dogs, Anxiety disorders, Animals, Scavengers, Wolves, Anxiety, Separation anxiety disorder, Human behavior

Having become accustomed to round-the-clock interactions with owners during COVID-19, veterinarians are deeply concerned that dogs will suffer severe separation anxiety when pet parents resume employment outside of the home.

Key Points: 
  • Having become accustomed to round-the-clock interactions with owners during COVID-19, veterinarians are deeply concerned that dogs will suffer severe separation anxiety when pet parents resume employment outside of the home.
  • Actions like putting on shoes, picking up keys, or opening the front door can trigger a dog's anxiety.
  • By creating new associations with such conduct, pups will be less likely to attribute them to mean their owners will be gone for 8-9 hours.
  • As well, ensure the location remains accessible even when parents are around so thatthe area isn't solely associated with the owner's absence.

Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc.

Retrieved on: 
Tuesday, July 14, 2020
Psychoactive drugs, Articles, Drugs, RTT, Entheogens, Posttraumatic stress disorder, Anxiety disorders, Stress, MDMA, System for Electronic Document Analysis and Retrieval, Psilocybin, Psychological trauma

In conjunction with a preeminent university in the EU, NeuroPharm will be initiating veteran-based clinical trials for the treatment of PTSD with microdosed MDMA/psilocybin formulations.

Key Points: 
  • In conjunction with a preeminent university in the EU, NeuroPharm will be initiating veteran-based clinical trials for the treatment of PTSD with microdosed MDMA/psilocybin formulations.
  • About Mydecine Innovations Group Inc.
    Mydecine Innovations Group is a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions.
  • NeuroPharm was founded by a dedicated group of former military personnel motivated to seek alternative treatments addressing these traumatic disorders experienced by many veterans following active service.
  • For further information about Mydecine Innovations Group Inc., please consult the Company's profile on SEDAR at www.sedar.com or visit the Company's website at http://www.mydecine.com

Social Anxiety Disorder Market Analysis 2020 - Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecasts, Drug Forecasts and Market Shares - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 23, 2020
Mental health, Health, Psychiatry, Anxiety disorders, RTT, Psychology, Psychiatric diagnosis, Medical diagnosis, Phobias, Abnormal psychology, Social anxiety disorder, Anxiety, Social anxiety, Anxiolytic

The "Global Social Anxiety Disorder Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Social Anxiety Disorder Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Social Anxiety Disorder pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Social Anxiety Disorder market size and drug sales.
  • Social Anxiety Disorder pipeline: Find out drugs in clinical trials for the treatment of Social Anxiety Disorder by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Social Anxiety Disorder drugs: Identify key drugs marketed and prescribed for Social Anxiety Disorder in the US, including trade name, molecule name, and company
    Social Anxiety Disorder drugs sales: Find out the sales value for Social Anxiety Disorder drugs by countries
    Social Anxiety Disorder market valuations: Find out the market size for Social Anxiety Disorder drugs in 2019 by countries.

Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder

Retrieved on: 
Thursday, June 18, 2020
Articles, Branches of biology, Psychiatry, Anxiety disorders, Mental health, Stress, Adverse childhood experiences, Posttraumatic stress disorder, Psychological trauma, NMDA receptor

The completion of enrollment in our Phase 2 exploratory study of PTSD represents an important clinical development milestone for our company, said Norbert Riedel, Ph.D., president and chief executive officer of Aptinyx.

Key Points: 
  • The completion of enrollment in our Phase 2 exploratory study of PTSD represents an important clinical development milestone for our company, said Norbert Riedel, Ph.D., president and chief executive officer of Aptinyx.
  • The Phase 2 study duration is ten to thirteen weeks overall, consisting of a screening period, two treatment periods, and a safety follow-up period.
  • The data from this first-in-patient, exploratory, Phase 2 study are expected to inform future development plans for NYX-783 in PTSD.
  • NYX-783 is a novel, oral NMDA receptor modulator currently in Phase 2 development for the treatment of post-traumatic stress disorder (PTSD).

Global Market Outlook for the Post-Traumatic Stress Disorder (PTSD) Therapeutics Market to 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 18, 2020
Pharmaceutical, Health, Mental health, Articles, Stress, Human behavior, Psychiatry, Adverse childhood experiences, Posttraumatic stress disorder, Anxiety disorders, Mental health, Post-traumatic, Traumatic stress, Trauma, Psychological trauma

The "Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • The global post-traumatic stress disorder (PSTD) therapeutics market is poised to grow by USD 909.86 mn during 2020-2024, progressing at a CAGR of 9% during the forecast period.
  • In addition, increasing initiatives by public and private organizations is anticipated to boost the growth of the post-traumatic stress disorder (PSTD) therapeutics market as well.
  • The global post-traumatic stress disorder (PSTD) therapeutics market is segmented as below:

Can a man rebuild his life from the brink of trauma and suicide?

Retrieved on: 
Monday, June 15, 2020
Articles, Posttraumatic stress disorder, Psychiatry, Human behavior, Anxiety disorders, Stress, Mental health, Adverse childhood experiences, Psychological trauma, Complex post-traumatic stress disorder, Posttraumatic stress disorder and substance use disorders

In his latest publication, Reinventing Life ( published by Balboa Press ), he shares his tumultuous journey with post-traumatic stress disorder (PTSD).

Key Points: 
  • In his latest publication, Reinventing Life ( published by Balboa Press ), he shares his tumultuous journey with post-traumatic stress disorder (PTSD).
  • This memoir follows the authors discovery of PTSD after the accident that caused him to become suicidal and opened deeply buried old wounds.
  • Here, Vogel describes the experience and how trauma altered his perceptions and reactions of family and community around him.
  • During my own drug-free recovery, I realized how PTSD slipped into my life unannounced and suddenly there it was.